Comment
Author: Admin | 2025-04-28
HomeQuilliChew ERGeneric Availability Last updated on Jan 8, 2025.See also: Generic Quillivant XRQuilliChew ER is a brand name of methylphenidate, approved by the FDA in the following formulation(s):QUILLICHEW ER (methylphenidate hydrochloride - tablet, extended release, chewable;oral) Manufacturer: NEXTWAVE PHARMS Approval date: December 4, 2015 Strength(s): 20MG [RLD], 30MG [RLD], 40MG [RLD] Has a generic version of QuilliChew ER been approved?No. There is currently no therapeutically equivalent version of QuilliChew ER available in the United States.Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of QuilliChew ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.See also: Generic Drug FAQ.Related patentsPatents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims. Methylphenidate extended release chewable tabletPatent 10,857,143Issued: December 8, 2020Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala KalyanAssignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.Patent expiration dates: August 14, 2033✓ Patent use: A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED✓ Drug product Methylphenidate extended release chewable tabletPatent 11,103,494Issued: August 31, 2021Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala KalyanAssignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.Patent expiration dates: August 14, 2033✓ Drug product Methylphenidate extended release chewable tabletPatent 11,103,495Issued: August 31, 2021Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala KalyanAssignee(s): TRIS PHARMA, INCAn oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate—ion exchange resin complex, a barrier
Add Comment